Trial Profile
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy Of Pomalidomide (CC-4047) In Subjects With Systemic Sclerosis with Interstitial Lung Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Interstitial lung diseases; Systemic scleroderma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Celgene Corporation
- 27 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Nov 2017 Owing to enrollment difficulty, the protocol was amended to increase the length of allowable disease duration (changed from 'onset of the first non-Raynaud SSc symptoms within 5 years prior to screening date' to 'onset of the first non-Raynaud symptoms to be within 7 years prior to screening'.)
- 01 Nov 2017 Results published in The Journal of Rheumatology